search
Back to results

Viral Load Triggered ART Care in Lesotho (VITAL)

Primary Purpose

HIV Infections

Status
Active
Phase
Not Applicable
Locations
Lesotho
Study Type
Interventional
Intervention
VITAL model
Sponsored by
Swiss Tropical & Public Health Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for HIV Infections

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

On an individual level, the inclusion criteria for the VITAL trial are the following:

  • Taking antiretroviral therapy (independent of viral suppression)
  • ≥ 18 years old
  • Written informed consent
  • intention to remain in the same facility for the duration of the trial
  • not enrolled in another study if judged as non-compatible by the (Local) Principal Investigator

On a cluster level, inclusion criteria for the VITAL trial are the following:

  • nurse-led public or missionary clinic in the districts of Butha-Buthe and Mokhotlong
  • consent of clinic management (signed agreement with clinic management)
  • access to the internet (internet connection must not be constant, but there must be possibility to down- and upload information daily)
  • the clinic sends VL samples to Butha-Buthe laboratory for analysis

Sites / Locations

  • Boiketsiso Health Center
  • Linakeng Health Center
  • Makhunoane Health Center
  • Motete Health Center
  • Muela Health Center
  • Ngoajane Health Center
  • Rampai Health Center
  • St Paul Health Center
  • St. Peters Health Center
  • Tsime Health Center
  • Libibing
  • Linakaneng health center
  • Malefiloane health center
  • Mapholaneng
  • Moeketsane
  • Molikaliko health center
  • St. James
  • St. Martins

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Intervention

Control

Arm Description

Clusters in the intervention arm receive the VITAL intervention (see intervention)

Clusters in the control arm continue standard of care.

Outcomes

Primary Outcome Measures

Engagement in care with documented viral suppression
Proportion of participants engaged in care (defined as documented visit attendance) with documented viral suppression (<20 copies/mL) 24 months (16-28 months) after enrollment

Secondary Outcome Measures

Viral re-suppression
Proportion of participants with viral re-suppression (<20 copies/mL) 24 months (16-28 months) after enrollment among all participants with an unsuppressed VL (≥ 20 copies/mL) during the first 12 months of follow-up
Sustained viral suppression
Proportion of participants with sustained viral suppression (defined as >1 VL <20 copies/mL) during 24 months (16-28 months) follow-up
Mortality rate
Proportion of participants with confirmed TB diagnosis
Disengagement from care
Proportion of participants disengaged from care (defined as no documented visit attendance) at 12 months (8-16 months) and 24 months (16-28 months) after enrollment
Time to follow-up viral load in case of an unsuppressed VL (≥ 20 copies/mL)
Time to switch of ART regimen in case of virologic failure
Rate of clinic visits
Proportion of participants switched to second-line ART
Proportion of participants switched to second-line ART at 12 and 24 months among participants with virologic failure
Proportion of participants diagnosed with TB
Proportion of participants receiving a course of TPT

Full Information

First Posted
March 9, 2020
Last Updated
May 19, 2023
Sponsor
Swiss Tropical & Public Health Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT04527874
Brief Title
Viral Load Triggered ART Care in Lesotho
Acronym
VITAL
Official Title
Assessment of a Viral Load Result-driven Automated Differentiated Service Delivery Model for Participants Taking Antiretroviral Therapy in Lesotho
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
October 14, 2020 (Actual)
Primary Completion Date
July 2024 (Anticipated)
Study Completion Date
July 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Swiss Tropical & Public Health Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This cluster randomized clinical trial at 18 nurse-led rural health centers in Lesotho will test an automated differentiated service delivery model using viral load results, other clinical characteristics and participants' preference to automatically triage participants into groups requiring different levels of attention and care.
Detailed Description
To sustainably provide good quality care to increasing numbers of people living with HIV (PLHIV) receiving antiretroviral therapy (ART), care delivery has to shift from a "one-size-fits-all" approach to differentiated care models. Such models should reallocate resources from patients who are doing well to patient groups who may need more attention, such as those with treatment failure or medical and psycho-social problems. Ideally, such a reallocation allows health systems and patients to save resources while improving quality of care. One proposed approach to differentiate care and intensity of monitoring is viral load-driven differentiated service delivery. Reducing the intensity of monitoring in patients with suppressed viral load (VL) and no other clinical problems would substantially reduce the workload at health care facilities and save time and transport cost for patients, thus potentially improve long-term engagement in care. Time and resources saved in patients with suppressed VL and no other clinical problems would allow focusing on those participants with elevated viral load and/or other clinical problems (like tuberculosis, which is the most common cause of mortality among PLHIV in sub-Saharan Africa). This may potentially improve PLHIVs' clinical outcome through intensified adherence support, clinical follow-up and timely switches to second-line ART. In many settings in sub-Saharan Africa, however, the potential of VL monitoring to differentiate care is not exploited and thus constitutes a missed opportunity. In Lesotho it was shown that the majority of unsuppressed VLs are not acted upon in a timely manner, be it due to providers and patients not being aware of the results or health care providers not being proficient in the management of treatment failure. The concept of the proposed automated differentiated service delivery model (aDSDM) is to use VL results, other clinical characteristics (TB screening results and CD4 cell counts) and participants' preference to automatically triage participants into groups requiring different levels of attention and care. Innovatively, triaging of participants will be done automatically capitalising on an existing VL database platform. The implemented aDSDM will differentiate care according to three elements: clinical characteristics (with focus on VL measurement) sub-population (women, men) participants' and health care providers' preferences To ensure effective flow of information, VL results and other relevant information is sent directly to participants' phones, whereas health care providers receive results directly on their study tablet together with the recommended action. Further features of the platform are preference-based tailored adherence reminders and automated calls to participants for symptomatic tuberculosis screening. The proposed aDSDM is designed for being scaled up at national and regional level as it mainly builds on automated triage and communication with participants and health care workers, thus not requiring additional human resources.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
cluster-randomized
Masking
None (Open Label)
Allocation
Randomized
Enrollment
5809 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention
Arm Type
Experimental
Arm Description
Clusters in the intervention arm receive the VITAL intervention (see intervention)
Arm Title
Control
Arm Type
No Intervention
Arm Description
Clusters in the control arm continue standard of care.
Intervention Type
Behavioral
Intervention Name(s)
VITAL model
Other Intervention Name(s)
automated differentiated service delivery
Intervention Description
The concept of the VITAL, an automated differentiated service delivery model (aDSDM), is to use viral load results, other clinical characteristics (TB screening results and CD4 cell counts, comorbidities) and participants' preference to automatically triage participants into groups requiring different levels of attention and care. Innovatively, triaging of participants will be done automatically making use of a dedicated mobile App and a viral load database platform. To ensure effective flow of information and empowerment of patients, viral load results and other relevant information is sent directly to participants' phones, whereas health care providers receive results directly on their study tablet together with the recommended action. Further features of the platform are preference-based tailored adherence reminders and automated calls to participants for symptomatic tuberculosis screening.
Primary Outcome Measure Information:
Title
Engagement in care with documented viral suppression
Description
Proportion of participants engaged in care (defined as documented visit attendance) with documented viral suppression (<20 copies/mL) 24 months (16-28 months) after enrollment
Time Frame
16-28 months after enrollment
Secondary Outcome Measure Information:
Title
Viral re-suppression
Description
Proportion of participants with viral re-suppression (<20 copies/mL) 24 months (16-28 months) after enrollment among all participants with an unsuppressed VL (≥ 20 copies/mL) during the first 12 months of follow-up
Time Frame
16-28 months after enrollment
Title
Sustained viral suppression
Description
Proportion of participants with sustained viral suppression (defined as >1 VL <20 copies/mL) during 24 months (16-28 months) follow-up
Time Frame
16-28 months after enrollment
Title
Mortality rate
Time Frame
at 12 and 24 months after enrollment
Title
Proportion of participants with confirmed TB diagnosis
Time Frame
at 12 and 24 months after enrollment
Title
Disengagement from care
Description
Proportion of participants disengaged from care (defined as no documented visit attendance) at 12 months (8-16 months) and 24 months (16-28 months) after enrollment
Time Frame
at 12 and 24 months after enrollment
Title
Time to follow-up viral load in case of an unsuppressed VL (≥ 20 copies/mL)
Time Frame
at 24 months after enrollment
Title
Time to switch of ART regimen in case of virologic failure
Time Frame
at 24 months after enrollment
Title
Rate of clinic visits
Time Frame
at 24 months after enrollment
Title
Proportion of participants switched to second-line ART
Description
Proportion of participants switched to second-line ART at 12 and 24 months among participants with virologic failure
Time Frame
at 12 and 24 months after enrollment
Title
Proportion of participants diagnosed with TB
Time Frame
at 12 and 24 months after enrollment
Title
Proportion of participants receiving a course of TPT
Time Frame
at 24 months after enrollment
Other Pre-specified Outcome Measures:
Title
Proportion of participants requesting a VL result notification through SMS
Description
in intervention clusters
Time Frame
at 24 months after enrollment
Title
Proportion of SMS delivered successfully
Description
in intervention clusters
Time Frame
at 24 months after enrollment
Title
Proportion of participants using the call-back option through District ART Nurse
Description
in intervention clusters
Time Frame
at 24 months after enrollment
Title
Proportion of participants screened positive fo TB by automated call
Description
in intervention clusters
Time Frame
at 24 months after enrollment
Title
Proportion of participants appreciating the automated differentiated service deliver model
Description
in intervention clusters
Time Frame
at 24 months after enrollment
Title
Proportion of health care providers appreciating the automated differentiated service delivery model
Description
in intervention clusters
Time Frame
at 24 months after enrollment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
On an individual level, the inclusion criteria for the VITAL trial are the following: Taking antiretroviral therapy (independent of viral suppression) ≥ 18 years old Written informed consent intention to remain in the same facility for the duration of the trial not enrolled in another study if judged as non-compatible by the (Local) Principal Investigator On a cluster level, inclusion criteria for the VITAL trial are the following: nurse-led public or missionary clinic in the districts of Butha-Buthe and Mokhotlong consent of clinic management (signed agreement with clinic management) access to the internet (internet connection must not be constant, but there must be possibility to down- and upload information daily) the clinic sends VL samples to Butha-Buthe laboratory for analysis
Facility Information:
Facility Name
Boiketsiso Health Center
City
Butha-Buthe
Country
Lesotho
Facility Name
Linakeng Health Center
City
Butha-Buthe
Country
Lesotho
Facility Name
Makhunoane Health Center
City
Butha-Buthe
Country
Lesotho
Facility Name
Motete Health Center
City
Butha-Buthe
Country
Lesotho
Facility Name
Muela Health Center
City
Butha-Buthe
Country
Lesotho
Facility Name
Ngoajane Health Center
City
Butha-Buthe
Country
Lesotho
Facility Name
Rampai Health Center
City
Butha-Buthe
Country
Lesotho
Facility Name
St Paul Health Center
City
Butha-Buthe
Country
Lesotho
Facility Name
St. Peters Health Center
City
Butha-Buthe
Country
Lesotho
Facility Name
Tsime Health Center
City
Butha-Buthe
Country
Lesotho
Facility Name
Libibing
City
Mokhotlong
Country
Lesotho
Facility Name
Linakaneng health center
City
Mokhotlong
Country
Lesotho
Facility Name
Malefiloane health center
City
Mokhotlong
Country
Lesotho
Facility Name
Mapholaneng
City
Mokhotlong
Country
Lesotho
Facility Name
Moeketsane
City
Mokhotlong
Country
Lesotho
Facility Name
Molikaliko health center
City
Mokhotlong
Country
Lesotho
Facility Name
St. James
City
Mokhotlong
Country
Lesotho
Facility Name
St. Martins
City
Mokhotlong
Country
Lesotho

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Time Frame
At publication of primary endpoint
IPD Sharing URL
https://www.zenodo.org
Citations:
PubMed Identifier
35511950
Citation
Tschumi N, Lerotholi M, Kopo M, Kao M, Lukau B, Nsakala B, Chejane N, Motaboli L, Lee T, Barnabas R, Shapiro AE, van Heerden A, Lejone TI, Amstutz A, Brown JA, Heitner J, Belus JM, Chammartin F, Labhardt ND. Assessment of a viral load result-triggered automated differentiated service delivery model for people taking ART in Lesotho (the VITAL study): Study protocol of a cluster-randomized trial. PLoS One. 2022 May 5;17(5):e0268100. doi: 10.1371/journal.pone.0268100. eCollection 2022.
Results Reference
derived

Learn more about this trial

Viral Load Triggered ART Care in Lesotho

We'll reach out to this number within 24 hrs